VIAject

Asset

Recombinant human insulin analog that binds to the insulin receptor to regulate glucose metabolism

Stage: Phase 2
Modality: Protein or enzyme
Target: Insulin/IGF-1 signalling; 1
Indication: 277
Trials: 1
Developer

Indications

1

Diabetes mellitus
Phase 2, Completed, NCT01000922, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Trials277
Evidence for its targets4
Competitors12
Aging relevance1
Signals4

Every asset’s record: target, stage, trials and the evidence behind it.